Neuronetics Inc (STIM) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The technical indicators suggest a bearish trend, and the company's financial performance shows significant challenges despite revenue growth. Additionally, there are no strong positive catalysts or trading signals to justify immediate action.

Technical Analysis

The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. MACD is below zero and negatively contracting, indicating weak momentum. RSI is neutral at 51.263, and the stock is trading below the pivot level of 1.464, with key support at 1.228 and resistance at 1.7.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Revenue increased significantly by 101.28% YoY in Q3 2025, showing potential growth in sales.

Neutral/Negative Catalysts

Net income dropped by -32.20% YoY, EPS declined by -70.45% YoY, and gross margin fell by -39.29% YoY. No recent news or significant trading trends from insiders or hedge funds. No recent congress trading data available.

Financial Performance

In Q3 2025, revenue increased to $37.297M (up 101.28% YoY), but net income dropped to -$9.045M (down -32.20% YoY). EPS declined to -0.13 (down -70.45% YoY), and gross margin decreased to 45.87% (down -39.29% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data available.

1 Analyst Rating

Wall Street analysts forecast STIM stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.340

Low

Averages

High

Current: 1.340

Low

Averages

High

Canaccord

William Plovanic

Buy

downgrade

$8 -> $7

AI Analysis

2025-08-06

Reason

Canaccord

William Plovanic

Price Target

$8 -> $7

AI Analysis

2025-08-06

downgrade

Buy

Reason

Canaccord analyst William Plovanic lowered the firm's price target on Neuronetics to $7 from $8 and keeps a Buy rating on the shares. The firm said they reported a Q2 beat driven by Clinic/Greenbrook revenue. Management reiterated its revenue guidance but brought down its Ggross margin guidance in light of Clinic revenue becoming a bigger mix of the business.

Citizens Capital Markets

Daniel Stauder

Buy

Maintains

$3 → $7

2025-03-05

Reason

Citizens Capital Markets

Daniel Stauder

Price Target

$3 → $7

2025-03-05

Maintains

Buy

Reason

Citizens JMP raised the firm's price target on Neuronetics to $7 from $3 and keeps an Outperform rating on the shares. Neuronetics' Top-line quarterly results came in moderately ahead of the company's mid-January preliminary announcement, and full-year 2025 guidance was maintained, the analyst tells investors in a research note. The stock's nearly 20% increase on Tuesday was most likely from additional commentary on what has been driving the stock higher year to date -- the potential growth, scale, and patient reach that the combined entity could achieve as a vertically integrated mental healthcare provider following the merger with Greenbrook TMS, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for STIM

Unlock Now

STIM Should I Buy

STIM Should I Buy

Should You Buy Neuronetics Inc (STIM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch